Author:
Petrillo Marco,Paris Ida,Vizzielli Giuseppe,Amadio Giulia,Cosentino Francesco,Salutari Vanda,Scambia Giovanni,Fagotti Anna
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.
2. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.
3. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in ovarian cancer. Version 1.2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian . Accessed 28th Nov 2014.
4. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2012;363:943–53.
5. Sehouli J, Papanikolaou G, Braicu EI, et al. Feasibility of surgery after systemic treatment with the humanized recombinant antibody bevacizumab in heavily pretreated patients with advanced epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1326–33.
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献